A Smart + Strong Site
Subscribe to:
Newsletters
POZ magazine
JOIN AIDSMEDS YouTube

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


emailprint

December 16, 2011

Chronic Hep B Doubles Risk of AIDS Illnesses and Death in People Living With HIV

Chronic hepatitis B virus (HBV) infection almost doubles the risk of AIDS or death in people diagnosed with HIV infection, compared with those only living with HIV, according to a new paper published ahead of print in The Journal of Infectious Diseases (JID). These important findings, the authors write, “may have implications for many aspects of HBV coinfection, including early diagnosis and, foremost, prevention of hepatitis B.”

Much like in people coinfected with HIV and hepatitis C virus (HCV), there is no shortage of evidence suggesting that HIV infection negatively affects HBV-related liver disease progression, including increased risks of end-stage liver disease and liver cancer. And while it is generally believed that chronic HCV infection doesn’t directly affect HIV disease progression—thought it can mean complex drug interactions between hepatitis C and HIV meds and hasten liver toxicity while using ARVs—it hasn’t been clear whether chronic HBV infection is an independent risk factor for HIV disease progression or death.

Unfortunately, the JID study results authored by Helen Chun, MD, of the National Naval Medical Center in Bethesda and her colleagues confirm earlier suggestions that HBV does negatively impact HIV outcomes.

The results come from the U.S. Military HIV Natural History Study, which has the advantage of including people who test positive for HIV while receiving care through a variety of Army- and Navy-based medical facilities throughout the country. This allowed Chun and her colleagues to focus specifically on 2,352 individuals whose date of HIV infection could be estimated within three years—thereby allowing the researchers to circumvent a common problem in disease progression studies, notably accounting for significant variations in patient duration of HIV infection—and whose HBV infection status was known or determined with two years of becoming infected with HIV.

Each patient’s HBV status was classified as being chronic (active infection), resolved (earlier infection followed by clearance and immunity), or no evidence of past or current infection.

Of the 2,352 recent HIV seroconverters in the study, 20 percent had resolved HBV infection and 3 percent had chronic HBV infection. Roughly 74 percent had no evidence of HBV infection. An additional 3 percent tested positive for hepatitis B “core” antibodies (HBcAb) alone, in the absence of other antibodies, which comes with a number of possible interpretations and generally requires more extensive testing. 

HIV-positive study subjects classified as having chronic HBV were twice as likely to die or develop an AIDS-defining illness, compared with those who were HBV negative. Even participants with resolved HBV infection or isolated HBcAb faced elevated risks of HIV disease progression or death, compared with HBV-negative individuals. Among those with resolved HBV infection, the relative risk was increased 35 percent. Among those with isolated HBcAb, the relative risk was increased 54 percent.

When Chun and her colleagues adjusted the data for confounding factors—for example, the date of HIV infection, given that nearly half of those included in the study were infected with HIV before 1996 when AIDS-related illnesses and death were much more common—the relative risk of developing an AIDS-related illness or dying among those with chronic HIV/HBV coinfection was still 80 percent higher compared with HIV-positive, HBV-negative individuals in the study.  Increases in the relative risks of AIDS-related illness or death were also documented in those with resolved HBV infection and isolated HBcAB in the adjusted analysis, but these increases were not statistically significant; they could have been due to chance.

Of note, HCV infection was also associated with an increased risk of developing an AIDS-related illness or death in the study. However, resolved or chronic HCV infection was uncommon in the cohort—only 1.7 percent were positive for HCV antibodies—and, thus, no firm conclusions could be drawn from this finding.

The reasons for the higher risks of AIDS-related illnesses and deaths were not apparent to Chun’s team. Chronic HBV infection did not appear to increase average viral load levels, in the absence of ARV treatment, nor did it appear to be associated with lower CD4 cell counts. In turn, the authors note, it is still necessary to determine “whether hepatitis B is a surrogate of poorer outcome or whether it has a direct harmful impact on HIV disease progression.”

While key questions remain, there are important lessons to be learned from this study, according to an accompanying editorial written by Philip Peters, MD, and Barbara Marston, MD, of the U.S. Centers for Disease Control and Prevention. “The analysis of [Chun’s group] moves us further toward an understanding of the increased mortality among persons with HIV/HBV coinfection. Although we remain with questions about whether HIV disease is indeed progressing more rapidly in these patients, there is no need to wait for answers before we amplify our response.”
Examples listed by Peters and Marston include stepped-up HBV vaccination efforts and the careful use of medications active against both HIV and HBV—such as Epivir (lamivudine), Emtriva (emtricitabine), Viread (tenofovir) or Truvada (tenofovir/emtricitabine)—in ARV drug regimens.

“There are undeniable barriers to achieving high rates of HBV vaccination and optimal treatment of HIV/HBV coinfection, both in the United States and internationally,” the CDC commentators note. “However, effective interventions exist and can be integrated into public health practice and clinical care.”

Search: hepatitis B, HBV, HIV, AIDS, morbidity, mortality, Chun, disease progression, vaccination, treatment, prevention


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (1 total)


[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    dlw8585
    Fort Lauderdale
    Florida


    zeze42
    Bay Area - Peninsula
    California


    hollywoodvers1
    Los Angeles
    California


    albsur7436
    San Francisco
    California
Click here to join POZ Personals!
Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014


21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014


7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.